Immunotherapy rechallenge after ICI-related pneumonitis in lung cancer patients: a retrospective cohort study
{{output}}
Background: Immune checkpoint inhibitors (ICIs) have significant advantages in treating lung cancer due to their low toxicity and high efficacy. However, adverse events, especially ICI-related pneumonitis (CIP), may restrict thei... ...
